IPF Drugs Approved by US FDA
October 29, 2014
The US FDA approves Esbriet® (pirfenidone) and Ofev® (nintedanib) for the treatment of idiopathic pulmonary fibrosis. Both drugs recently received the FDA’s “breakthrough therapy” designation, which accelerated the FDA review process. Esbriet is manufactured by InterMune, Inc. and Ofev is distributed by Boehringer Ingelheim Pharmaceuticals, Inc.
